SG Americas Securities LLC Makes New $138,000 Investment in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

SG Americas Securities LLC purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the second quarter, HoldingsChannel.com reports. The fund purchased 4,566 shares of the company’s stock, valued at approximately $138,000.

Several other hedge funds have also recently bought and sold shares of HRMY. Quadrant Capital Group LLC lifted its position in Harmony Biosciences by 47.5% in the 4th quarter. Quadrant Capital Group LLC now owns 1,022 shares of the company’s stock valued at $33,000 after acquiring an additional 329 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Harmony Biosciences by 1.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 35,272 shares of the company’s stock valued at $1,184,000 after purchasing an additional 397 shares in the last quarter. Texas Permanent School Fund Corp boosted its position in shares of Harmony Biosciences by 1.8% during the first quarter. Texas Permanent School Fund Corp now owns 28,706 shares of the company’s stock worth $964,000 after buying an additional 517 shares during the period. ProShare Advisors LLC grew its holdings in shares of Harmony Biosciences by 7.0% during the first quarter. ProShare Advisors LLC now owns 10,488 shares of the company’s stock worth $352,000 after buying an additional 684 shares in the last quarter. Finally, TFO Wealth Partners LLC grew its holdings in shares of Harmony Biosciences by 98,700.0% during the fourth quarter. TFO Wealth Partners LLC now owns 988 shares of the company’s stock worth $32,000 after buying an additional 987 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Trading Up 1.0 %

NASDAQ HRMY opened at $36.36 on Monday. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.26. The company has a current ratio of 3.11, a quick ratio of 3.07 and a debt-to-equity ratio of 0.34. The stock has a 50 day moving average of $32.81 and a 200-day moving average of $31.67. The company has a market cap of $2.06 billion, a PE ratio of 15.74, a PEG ratio of 0.81 and a beta of 0.72.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.24. Harmony Biosciences had a net margin of 22.30% and a return on equity of 28.26%. The firm had revenue of $172.80 million for the quarter, compared to analyst estimates of $172.53 million. During the same period in the prior year, the firm posted $0.56 earnings per share. The company’s quarterly revenue was up 28.8% compared to the same quarter last year. On average, equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 1.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on HRMY shares. Citigroup assumed coverage on Harmony Biosciences in a research report on Friday, June 21st. They set a “buy” rating and a $48.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.67.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.